CNS Anticancer Drug Discovery and Development Conference
November 16 - 17, 2016
Fairmont Princess Hotel, Scottsdale, Arizona
Building on the success of the first meeting in 2014, the Society for Neuro-Oncology is pleased to host the second CNS Anticancer Drug Discovery and Development Conference, which will be held November 16 - 17, 2016 at the Fairmont Princess Hotel in Scottsdale, Arizona, immediately prior to the 21st Annual SNO Meeting.
The conference, organized by academic and pharmaceutical industry scientists and physicians, is intended to improve drug discovery and development for primary infiltrative tumors in adults and children as well as tumors that metastasize to the CNS. It will provide education and networking opportunities for scientists in academia, government, and the pharmaceutical industry that will, we hope, foster greater collaboration and, thereby, improve patient outcomes.
Begins Wednesday, November 16, 8:00am
Concludes Thursday, November 17, 4:00pm
To register for the conference, click here.
*Please note that separate registration is required for the SNO Annual Meeting.
Hotel reservations must be made online. To reserve a room, click here.
CLICK HERE to view the Preliminary Program
The program will feature presentations by the following key leaders in academia, government and industry, as well as selected abstract presentations.
Session 1: Clinical Reality and Pharmaceutical Challenges
- Challenges for the treatment of infiltrative and secondary CNS tumors and overview of conference – Victor Levin (UT MDACC & UCSF)
- Prediction of BBB transport and CNS drug distribution; considerations for anticancer drugs – Elisabeth de Lange, PhD (Leiden Univ)
- Integrating drug-target kinetics into predictions of in vivo drug activity – Peter Tonge, PhD (Stony Brook University)
- Small molecule kinase inhibitors for brain cancer: limitations, challenges and opportunities - Tim Heffron, PhD (Genentech)
Session 2: Economic and Regulatory Challenges
- Leaving Breakthrough Drugs on the Laboratory Shelf: How the Patent System Distorts Industry Drug Development, and How to Fix It – Benjamin Roin, BA, JD (MIT)
- Regulatory perspectives on developing products for rare tumors - Joohee Sul, FDA
- Industry challenges to develop therapies for CNS cancers - Lauren Abrey, F. Hoffmann-La Roche Ltd.
Session 3: Drug Targets and Brain Penetrant Drugs
- A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma – William Bill Weiss, MD, PhD (UCSF)
- The discovery and early clinical development of AZD3759, a fully BBB-penetrant EGFR kinase inhibitor – Xiaolin Zhang, PhD (Astra - Zeneca and Innovative Center China)
- Clinical development of IDH inhibitors in glioma – Chris Bowden, MD (Agios)
Session 4: Imaging of Drugs and Drug Effects in the CNS
- Emerging Strategies in the Molecular Imaging of Brain Tumors – Sanjiv Sam Gambhir, MD, PhD (Stanford)
- MRI and using humans as the experimental model in drug development – Elizabeth Gerstner, MD (MGH)
- Visualizing human neurochemical (dys)function using positron emission tomography – Frederick A. Schroeder (Massaschusetts General)
- Hyperpolarized 13C Magnetic Resonance Spectroscopic Imaging of Brain Tumors and their Response to Therapy – Sabrina Ronen, PhD (UCSF)
Session 5: New Types of Drugs and Drug Delivery Opportunities
- Modular nanomedicine for brain and spinal cord-targeted chemotherapy - Rachael Sirianni, PhD (AZU)
- Increasing drug-target residence time by covalent interactions – Jack Taunton, PhD (UCSF)
Session 6: Modeling Drug Effects and Tumor Growth
- Patient-specific mathematical neuro-oncology: Identifying and predicting response - Kristin Swanson, PhD (Mayo Clinic)
- Towards integrated mechanistic models of glioblastoma signaling for precision pharmacology - Marc Birtwistle, PhD (Mt Sinai)
- Mice: The worst pre-clinical models...except for all the others – Robert J. Wechsler-Reya, PhD (Sanford Burnham Prebys Medical Discovery Institute)
- Phase I trials: bridging the divide between preclinical results and the clinic - Alexander (Sandy) Anderson (Moffitt Cancer Center)
Session 7: Drug Targets and the CNS Tumor Micro-Environment
- Modulation of glioblastoma tumorigenicity by tumor microenvironment – Clark Chen, MD, PhD (UCSD)
- Brain microenvironment-induced PTEN loss primes tumor outgrowth that can be suppressed by targeting CCL2 - Dihua Yu, MD, PhD (UT M.D. Anderson Cancer Center)
Conference generously supported by: